Taxanes in Combination with Cisplatin and Fluorouracil for Advanced Penile Cancer: Preliminary Results

Inguinal Lymph Nodes in Carcinoma Penis-Observation or Surgery?

“…The incidence of distant disease at the time of diagnosis is between 1.9% and 7.0% [30]. Although, chemotherapy and radiation therapy can be considered in these patients for palliation but survival is very poor.…”

Multiple Cutaneous Metastasis from Carcinoma of the Penis—Report of Two Cases

“…Khandpur et al also used similar chemotherapy regimen for 3 cycles and had complete response of the metastatic skin lesions along with significant decrease of the lesions in the penis and ilio-ingiunal nodes [5]. More recently, newer chemotherapeutic regimes were tried combining paclitaxel with cisplatinum and 5FU which showed higher activity with lesser toxicity [9]. Some centers have tried targeted therapy using cetuximab or panitumubab either alone or in combination with chemotherapy and have reported relevant response [6,7].…”

Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)

“…Pizzocaro and colleagues also evaluated patients treated with either 12 weeks of vinblastine-bleomycin-methotrexate (VBM) or cisplatin-5-FU in the adjuvant setting. 84 Adjuvant VBM was associated with an 84% disease-free survival compared to 39% in historic controls. However, treatment with bleomycin in these studies was associated with significant…”

“…The addition of a taxane to cisplatin-5-FU (TPF) yielded improved pathologic responses and survival in a small series. 84 The use of neoadjuvant paclitaxel-cisplatin-ifosphomide (TIP) resulted in several pT0 events in a retrospective analysis of 10 patients with lymphadenopathy greater than 4 cm. 82 This regimen has been evaluated further by Pagliaro and colleagues.…”

“…Pizzocaro and colleagues used a neoadjuvant regimen of paclitaxel/ cisplatinum and 5-FU and reported a response in all 3 patients treated. 84 For patients with penile carcinoma and fixed inguinal lymph node metastases or mobile nodes of 4 cm or greater, neoadjuvant chemotherapy followed by lymph node dissection should be given to patients whose disease responds to treatment. There is also likely to be a benefit in patients with N2 disease, but data are lacking.…”